Anondita medicare limited has secured a confirmed supply order worth Rs 8.01 crore from Central Medical Services Society (Cmss), Ministry of Health and Family Welfare, Government of India, for the supply of 8,00,62,000 pieces of condoms under the Family Planning Programme. The order was disclosed to exchanges on September 2, 2026.

Order in Financial Context

At Rs 8.01 crore, this order represents a smaller-ticket addition relative to Anondita medicare's FY26 consolidated annual revenue of Rs 137.42 crore; on a quarterly basis, the implied average is approximately Rs 34 crore per quarter, placing this order at roughly 23% of a single quarter's revenue run-rate. The total disclosed order inflow for Q1FY27 (Apr-Jun 2026) stood at Rs 105.47 crore across 6 orders (sum of the 6 orders disclosed across the last fiscal quarter shown in the table below), with the current order falling in Q2FY27. Using FY26 revenue of Rs 137.42 crore as the TTM base, the Q1FY27 disclosed inflow alone represents a book-to-bill of approximately 0.77x for that quarter, though the current order and any undisclosed wins in Q2FY27 would add to this. Quarterly revenue breakdown data is not available in the current filing; the coverage figure in quarters cannot be precisely stated without a pre-computed backlog total that includes Q2FY27 additions.

Company Order Track Record

Order inflow in Q1FY27 was concentrated in April-June 2026, with the Rs 43.14 crore Supra Healthcare Johannesburg international order being the largest single disclosed win, alongside two Cmss domestic government orders totalling approximately Rs 10.11 crore and two smaller domestic trade orders. The current Rs 8.01 crore Cmss order is consistent with the per-order size visible in the domestic government segment of the history, where individual Cmss orders have ranged from Rs 2.92 crore to Rs 7.18 crore. Inflow velocity across the single available quarter is not sufficient to establish an acceleration or deceleration trend; only one quarter of pre-computed data is available.

Execution and Revenue Quality

Quarterly revenue, net profit, and OPM data are not available in the provided inputs. On an annual basis, Anondita medicare's consolidated revenue grew from Rs 77.10 crore in FY25 to Rs 137.42 crore in FY26, with net profit expanding from Rs 16.40 crore to Rs 36.15 crore and OPM improving from 33.32% to 36.87%. No quarterly execution table can be constructed from the available data.

| Quarter | Revenue (Rs Cr) | Net Profit (Rs Cr) | OPM (%) | | :--- | :--- | :--- | | FY26 (Annual) | 137.42 | 36.15 | 36.87% | | FY25 (Annual) | 77.10 | 16.40 | 33.32% |

Revenue Growth - Order Wins Translating to Revenue

As Anondita medicare has sustained order wins across both domestic government procurement channels (Cmss) and international markets (Supra Healthcare Johannesburg), its annual consolidated revenue has grown from Rs 77.10 crore in FY25 to Rs 137.42 crore in FY26, representing a YoY growth of 78.2% based on the latest annual data. Net profit growth of 120.4% over the same period indicates that operating leverage is amplifying revenue gains at the bottom line. The FY25 data represents the earliest available annual comparison point in the provided financials.

Working Capital and Execution Capacity

The FY26 consolidated balance sheet shows a current ratio of 3.57x and Total Liabilities/Equity of 0.43x, indicating the company carries limited external liabilities relative to equity and has comfortable near-term liquidity to support order execution. Reserve and surplus of Rs 111.20 crore against total equity of Rs 129.20 crore reflects a largely internally funded balance sheet. However, operating cashflow was negative at Rs -10.50 crore in FY25 with free cashflow (proxy) at Rs -30.40 crore, driven in part by capex of Rs -19.90 crore; this signals that working capital and investment outflows were absorbing cash even as the business was growing, and the FY26 cashflow position is not yet available to confirm whether this has reversed.

What to Watch

• Execution rate: With FY26 annual revenue at Rs 137.42 crore and order inflow in Q1FY27 alone at Rs 105.47 crore, the quarterly revenue run-rate relative to the growing order book is the primary metric to track; watch whether Q2FY27 and subsequent quarters show accelerating revenue conversion.
• OPM trajectory: FY26 OPM of 36.87% is above FY25's 33.32%; whether new government supply orders (typically fixed-price tenders) sustain or compress this margin as volumes scale is a key execution quality indicator.
• Client concentration: Cmss (Ministry of Health and Family Welfare) appears across multiple orders in the disclosed history; if Cmss-linked orders account for a dominant share of the total disclosed order book, any change in government procurement policy or tender award timing would carry outsized revenue risk.
• Cash conversion: Operating cashflow turned negative in FY25 despite revenue growth; FY26 cashflow data, when disclosed, will clarify whether the working capital cycle has tightened as the business scaled.

Key Observations

• Promoter holding: Promoter stake moved from 83.95% in Q3FY25 to 61.71% in Q2FY26, a decline of 22.24 percentage points. This is a material change and the context (whether via IPO, QIP, or secondary sale) is not stated in the filing data.
• Cash conversion: Operating cashflow of -Rs 10.50 crore in FY25; backlog is not converting to cash efficiently, and receivables or working capital cycle may be stretched. FY26 cashflow data is not yet available in the provided inputs.
• Revenue scale vs. order size: The current Rs 8.01 crore Cmss order is individually small relative to FY26 annual revenue of Rs 137.42 crore, but Cmss has been a repeat awarding entity across multiple quarters, suggesting a recurring revenue stream from government family planning procurement rather than lumpy project-based inflows.
• International exposure: The Rs 43.14 crore Supra Healthcare Johannesburg order in Q1FY27 represents a meaningful share of a single quarter's implied revenue run-rate; currency and delivery risk on 50 forty-foot containers of export supply is a factor not quantified in the filing.

Anondita Medicare Limited has approved the preferential allotment of 2,85,000 warrants to persons belonging to the promoter category, aggregating to ₹29.58 crore. The Board of Directors approved the issuance in a meeting held on July 08, 2026, to raise funds through the allotment of convertible warrants.

The warrants have been allotted to Mr. Anupam Ghosh at a price of ₹1,038 per warrant, which includes a premium of ₹1,028. Each warrant carries the right to subscribe to one equity share with a face value of ₹10. The tenure of the warrants is up to 18 months from the date of allotment, and they may be converted in one or more tranches.

Payment Structure and Terms

The payment structure requires the allottee to pay 25% of the warrant issue price at the time of subscription. The remaining 75% will be payable at the time of allotment of equity shares upon the exercise of the option attached to the warrants. If the warrants are not exercised within the 18-month tenure, they will lapse, and the initial amount paid will be forfeited by the company.

Shareholding Pattern

The preferential issue will impact the shareholding of the promoter upon full conversion of the warrants into equity shares. The following table outlines the pre and post-issue shareholding details:

*Assuming full conversion of 2,85,000 Warrants proposed to be issued and allotted to Proposed Allottees into 2,85,000 equity shares of the Company.

The issuance is being conducted in accordance with Chapter V of the SEBI ICDR Regulations and other applicable laws. The floor price calculated as per Regulation 164 was ₹10 per warrant, though the company has set the issue price at ₹1,038 per warrant.